E
Sangamo Therapeutics, Inc. SGMO
$0.5701 -$0.0857-13.07%
Recommendation
Sell
Prev Close
$0.82
Volume
13,772,631
Avg Vol (90D)
6,143,762
Market Cap
$184.26M
Dividend & Yield
--
52-Week Range
$0.304 - $3.18
P/E (TTM)
--
EPS (TTM)
-$0.5189
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
D
Weak
Rating Factors
Growth Index
Very Weak
Efficiency Index
Very Weak
Solvency Index
Good
Total Return Index
Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Sangamo Therapeutics (NASDAQ:SGMO) Receives Sector Perform Rating from Royal Bank of Canada
3/19/2025 - MarketBeat
Sangamo Therapeutics Full Year 2024 Earnings: Misses Expectations
3/19/2025 - Simply Wall St
Sangamo Therapeutics (NASDAQ:SGMO) Announces Earnings Results, Misses Estimates By $0.02 EPS
3/18/2025 - MarketBeat
Sangamo Therapeutics (NASDAQ:SGMO) Posts Earnings Results
3/18/2025 - MarketBeat
Sangamo Therapeutics Inc (SGMO) Q4 2024 Earnings Call Highlights: Strategic Advances and ...
3/18/2025 - GuruFocus
Sangamo Therapeutics Retail Traders Keep The Faith Even As Stock Slides After-Hours On Q4 Miss
3/18/2025 - Stocktwits News Feed
Q4 2024 Sangamo Therapeutics Inc Earnings Call Transcript
3/18/2025 - GuruFocus
Sangamo Therapeutics Advances Neurology Pipeline Amid Financial Restructuring
3/18/2025 - TipRanks Financial Blog
Sangamo Therapeutics, Inc. (SGMO) Q4 2024 Earnings Call Transcript
3/17/2025 - Seeking Alpha: Transcripts
Sangamo Therapeutics, Inc. (SGMO) Q4 2024 Earnings Call Transcript
3/17/2025 - SeekingAlpha
Sangamo Therapeutics (SGMO) Reports Q4 Loss, Misses Revenue Estimates
3/17/2025 - Zacks Investment Research
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 ...
3/17/2025 - GuruFocus
Sangamo Therapeutics, Inc. 2024 Q4 - Results - Earnings Call Presentation
3/17/2025 - SeekingAlpha
Sangamo Therapeutics Q4 2024 Earnings: EPS of -$0.11 Misses Estimate, Revenue Falls Short at $7. ...
3/17/2025 - GuruFocus
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
3/17/2025 - Business Wire
Sangamo Therapeutics Q4 Earnings Preview
3/16/2025 - SeekingAlpha.com: All News
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Average Rating of "Moderate Buy" from Brokerages
3/16/2025 - MarketBeat
Sangamo Therapeutics (SGMO) Expected to Announce Earnings on Monday
3/15/2025 - MarketBeat
Sangamo Therapeutics Target of Unusually High Options Trading (NASDAQ:SGMO)
3/13/2025 - MarketBeat
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and ...
3/6/2025 - GuruFocus
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and ...
3/6/2025 - GuruFocus
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2024 Earnings Call and Participation in Upcoming Investor Conference
3/6/2025 - Business Wire
Sangamo Therapeutics (SGMO) Projected to Post Earnings on Wednesday
3/5/2025 - MarketBeat
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Looks Inexpensive After Falling 25% But Perhaps Not Attractive Enough
3/4/2025 - Simply Wall St
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Receives Consensus Rating of "Moderate Buy" from Brokerages
2/19/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$57.80M
EBITDA (TTM)
-$93.24M
EBIT (TTM)
-$98.35M
Net Income (TTM)
-$97.94M
Balance Sheet
Total Assets (Q)
$101.64M
Total Debt (Q)
$30.57M
Total Liabilities (Q)
$78.87M
Book Value Per Share (Q)
$0.107
Cash Flow
Cash from Operations (TTM)
-$67.14M
Cash from Investing (TTM)
$37.52M
Cash from Financing (TTM)
$28.38M
Net Change in Cash (TTM)
-$3.29M
Filings
Filing Date
Monday, March 17, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 5 and 9 (est)
Price History
Loading...
Beta
0.08
7-Day Total Return
-32.06%
30-Day Total Return
-51.27%
60-Day Total Return
-44.11%
90-Day Total Return
-72.19%
Year to Date Total Return
-49.55%
1-Year Total Return
-6.17%
2-Year Total Return
-67.61%
3-Year Total Return
-90.92%
5-Year Total Return
-91.22%
52-week Low
Jul 05, 2024 - $0.304
52-week High
Nov 08, 2024 - $3.18
Valuation
Market Cap
$184.26M - Micro Cap
Enterprise Value
$172.91M
Price/Sales (TTM)
2.98
Price/Book (Q)
7.66
Dividends and Shares
Shares Outstanding
210.19M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.sangamo.com
Phone Number
510 970 6000
Address
501 Canal Blvd
Richmond, CA 94804
Country
United States
Year Founded
1995
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious... more
NASDAQ 04/01/2025 4:00PM Eastern Quotes delayed
Weiss Ratings